Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.

1.
Cavallari
LH
,
Lee
CR
,
Duarte
JD
,
Nutescu
EA
,
Weitzel
KW
,
Stouffer
GA
,
Johnson
JA
:
Implementation of inpatient models of pharmacogenetics programs.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
2016
;73:1944-1954.
2.
Arwood
MJ
,
Chumnumwat
S
,
Cavallari
LH
,
Nutescu
EA
,
Duarte
JD
.
Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges
.
Clin Transl Sci
.
2016
Oct
;
9
(
5
):
233
45
.
[PubMed]
1752-8054
3.
Shuldiner
AR
,
Relling
MV
,
Peterson
JF
,
Hicks
JK
,
Freimuth
RR
,
Sadee
W
, et al.;
Pharmacogenomics Research Network Translational Pharmacogenetics Program Group
.
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation
.
Clin Pharmacol Ther
.
2013
Aug
;
94
(
2
):
207
10
.
[PubMed]
0009-9236
4.
Relling
MV
,
Krauss
RM
,
Roden
DM
,
Klein
TE
,
Fowler
DM
,
Terada
N
, et al.
New pharmacogenomics research network: an open community catalyzing research and translation in precision medicine
.
Clin Pharmacol Ther
.
2017
Dec
;
102
(
6
):
897
902
.
[PubMed]
0009-9236
5.
Weitzel
KW
,
Alexander
M
,
Bernhardt
BA
,
Calman
N
,
Carey
DJ
,
Cavallari
LH
, et al.;
IGNITE Network
.
The IGNITE network: a model for genomic medicine implementation and research
.
BMC Med Genomics
.
2016
Jan
;
9
(
1
):
1
.
[PubMed]
1755-8794
6.
South east asian pharmacogenomics research network. Pharmacogenomics network in asean [internet].
2018
[cited 2018 november 20]. Available from: Http://www.Pharmagtc.Org/seapharm/index.Php/seapharm/about-seapharm
7.
Yoshihama
T
,
Fukunaga
K
,
Hirasawa
A
,
Nomura
H
,
Akahane
T
,
Kataoka
F
, et al.
GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes
.
Oncotarget
.
2018
Jul
;
9
(
51
):
29789
800
.
[PubMed]
1949-2553
8.
Mizzi
C
,
Dalabira
E
,
Kumuthini
J
,
Dzimiri
N
,
Balogh
I
,
Başak
N
, et al.
A european spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics
.
PLoS One
.
2016
Sep
;
11
(
9
):
e0162866
.
[PubMed]
1932-6203
9.
van der Wouden
CH
,
Cambon-Thomsen
A
,
Cecchin
E
,
Cheung
KC
,
Dávila-Fajardo
CL
,
Deneer
VH
, et al.;
Ubiquitous Pharmacogenomics Consortium
.
Implementing pharmacogenomics in europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium
.
Clin Pharmacol Ther
.
2017
Mar
;
101
(
3
):
341
58
.
[PubMed]
0009-9236
10.
Sosa-Macías
M
,
Teran
E
,
Waters
W
,
Fors
MM
,
Altamirano
C
,
Jung-Cook
H
, et al.
Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America
.
Pharmacogenomics
.
2016
Nov
;
17
(
16
):
1741
7
.
[PubMed]
1462-2416
11.
Central intelligence agency. The world factbook; south asia: Nepal [internet].
2018
[cited 2019 may 9]. Available from: Https://www.Cia.Gov/library/publications/the-world-factbook/geos/np.Html
12.
Siva
N
.
1000 Genomes project
.
Nat Biotechnol
.
2008
Mar
;
26
(
3
):
256
.
[PubMed]
1087-0156
13.
Uppsala monitoring center [internet]. Members of the who programme for international drug monitoring [cited 2018 november 20]. Available from:Https://www.Who-umc.Org/global-pharmacovigilance/members/who-programme-members/
14.
Conti
R
,
Veenstra
DL
,
Armstrong
K
,
Lesko
LJ
,
Grosse
SD
.
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities
.
Med Decis Making
.
2010
May-Jun
;
30
(
3
):
328
40
.
[PubMed]
0272-989X
15.
Weitzel
KW
,
Aquilante
CL
,
Johnson
S
,
Kisor
DF
,
Empey
PE
:
Educational strategies to enable expansion of pharmacogenomics-based care.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
2016
;73:1986-1998.
16.
Klein
ME
,
Parvez
MM
,
Shin
JG
.
Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions
.
J Pharm Sci
.
2017
Sep
;
106
(
9
):
2368
79
.
[PubMed]
0022-3549
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.